BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2714732)

  • 1. Interaction between moclobemide and oral tyramine in depressed patients.
    Burgess CD; Mellsop GW
    Fundam Clin Pharmacol; 1989; 3(1):47-52. PubMed ID: 2714732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW; Maguire KP; Davies BM
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R; Fischbach R; Breuel HP
    Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
    Simpson GM; Gratz SS
    Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
    Gieschke R; Schmid-Burgk W; Amrein R
    J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
    Korn A; Da Prada M; Raffesberg W; Allen S; Gasic S
    J Neural Transm Suppl; 1988; 26():57-71. PubMed ID: 3162952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
    Norman TR; Burrows GD
    Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
    Korn A; Wagner B; Moritz E; Dingemanse J
    Eur J Clin Pharmacol; 1996; 49(4):273-8. PubMed ID: 8857072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers.
    Berlin I; Zimmer R; Cournot A; Payan C; Pedarriosse AM; Puech AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):344-51. PubMed ID: 2673623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
    Versiani M; Nardi AE; Figueira IL; Stabl M
    Acta Psychiatr Scand Suppl; 1990; 360():24-8. PubMed ID: 2123366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RIMA--a new concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):123-32. PubMed ID: 8468432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen.
    Müller T; Gieschke R; Ziegler WH
    J Neural Transm Suppl; 1988; 26():105-14. PubMed ID: 3162949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moclobemide (Ro 11-1163) versus tranylcypromine in the treatment of endogenous depression.
    Gabelic I; Kuhn B
    Acta Psychiatr Scand Suppl; 1990; 360():63. PubMed ID: 2248076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R
    Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction.
    Youdim MB
    Acta Psychiatr Scand Suppl; 1995; 386():5-7. PubMed ID: 7717095
    [No Abstract]   [Full Text] [Related]  

  • 16. An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression.
    Evans L; George T; O'Sullivan B; Mitchell P; Johnson G; Adena M
    Aust N Z J Psychiatry; 1992 Sep; 26(3):454-8. PubMed ID: 1417632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Moclobemide].
    Gleiter C; Volz HP
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852
    [No Abstract]   [Full Text] [Related]  

  • 18. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
    Korn A; Eichler HG; Fischbach R; Gasic S
    Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
    Da Prada M; Burkard WP
    Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
    Dingemanse J; Hussain Y; Korn A
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.